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We read with interest the study by
Riveiro-Falkenbach et al. (2015)
reporting a strong intra- and inter-
tumor homogeneity of BRAFV600E
mutation in melanoma samples. In
their study, the authors demonstrated
that adding immunohistochemistry
(IHC) with a BRAFV600E mutation-
specific antibody (clone VE1) to routine
molecular methods (Cobas 4800
BRAFV600 test in their study) avoided
false-negative results in the detection of
this particular BRAF mutation. Some
studies reported remarkable rates of
intra- and intertumor heterogeneity of
BRAF mutations in melanoma tumors
(Bradish et al., 2015; Colombino et al.,
2012; Yancovitz et al., 2012). To the
contrary, other studies demonstrated
a high homogeneity in the expression
of the BRAFV600E mutant protein,
using notably BRAFV600E IHC, be-
tween and within melanoma samples
(Boursault et al., 2013; Long et al.,
2013; Menzies et al., 2014). Riveiro-
Falkenbach et al. hypothesized that the
false negativity of the molecular
methods in the detection of BRAFV600
mutation would be responsible for most
of the reported BRAFV600 mutational
heterogeneity between paired tumor
samples in patients with metastatic
melanomas. Indeed, in our daily prac-
tice of BRAF analysis, using pyrose-
quencing andBRAFV600E IHC,wehave
to date encountered no intertumor
discrepancy in patients with multiple
melanoma samples (25 patients). This
supports the conclusions by Riveiro-
Falkenbach et al.
As hypothesized by many authors,
true intertumoral discrepant BRAF
mutational status would reflect more
the existence of two different primary
melanomas with different mutational
status and independent evolutions
rather than the BRAFV600 mutational
evolution of a melanoma during itsAbbreviation: IHC, immunohistochemistry
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2013; Long et al., 2013). The advantage
of BRAFV600E IHC compared with
DNA-based methods is to point out the
strong homogeneity in the expression of
the mutant protein by the tumor cells
within a melanoma sample. This strong
IHC homogeneity has also been re-
ported in other studies using
BRAFV600E IHC arguing against the
existence of distinct BRAFV600E
mutated and not mutated tumor
clones within a sample. Cases of het-
erogeneous staining are thought to be
more IHC technical artifacts than true
intratumor heterogeneity (Boursault
et al., 2013; Busam et al., 2013;
Colomba et al., 2013; Fisher et al.,
2014; Long et al., 2013; Menzies
et al., 2014; Riveiro-Falkenbach et al.,
2015). With advances in targeted
therapies in the field of metastatic
melanoma, this consideration of
tumor heterogeneity/homogeneity is
important to adapt the molecular
screening strategy and, as a conse-
quence, the therapeutic management of
the patients.
Besides BRAF inhibitors, new targeted
therapies, notably the development of
MEK inhibitors, permit treatment of not
only BRAF-mutated but also NRAS-
mutated melanomas (Johnson and
Puzanov, 2015). In this manner,
screening for NRAS mutations is now
routinely performed for therapeutic
management of patients with metastatic
melanoma. About 15e20% of mela-
nomas are NRAS mutated, mainly in
codon 61 with a predominant
NRASQ61Rmutation (about 40% of the
NRASQ61 mutants) (Ilie et al., 2015;
Platz et al., 2008). Questions about the
distribution of NRAS mutation within a
sample and between paired samples are
the same as those studied by Riveiro-
Falkenbach et al. about BRAFV600 mu-
tations. In this letter we report our
experience onmutational homogeneity/015heterogeneity in patients with NRAS-
mutated melanomas.
In our daily practice, based on
pyrosequencing and more recently IHC
analyses, we have observed no inter-
tumor discrepant NRAS mutational
status in 18 patients with multiple
melanoma samples (12 NRASQ61R, 4
NRASQ61K, and 2 NRASQ61L muta-
tions). As an ancillary test to molecular
methods, we routinely use NRASQ61R
mutation-specific IHC (clone SP174) in
the mutational screening of patients
with advanced stages of melanomas.
This recently described SP174 antibody
is reported to be highly sensitive and
specific to detect this particular
NRASQ61R mutant in melanoma (Ilie
et al., 2015; Massi et al., 2014). It also
permits quantification of the proportion
of cells expressing the mutant protein
within a tumor. In our file of
NRASQ61R IHC-positive melanomas
(38 tumors), the mean proportion of
stained cells is 82% (range, 10e100%).
These data are concordant with the re-
sults of Massi et al. (2014) and Ilie et al.
(2015) on NRASQ61R IHC. This also
supports a strong homogeneity of most
melanomas concerning the distribution
of NRASQ61R mutation. We hypothe-
size, as do Riveiro-Falkenbach et al.,
that the unstained areas using
NRASQ61R IHC seem to be more
related to IHC technical artifacts than
to true intratumor heterogeneity,
explaining the low percentage of IHC-
positive cells in some of our samples,
with potential issues due to inhomoge-
neous fixation process (Figure 1). This
hypothesis is supported by the weaker
intensity of IHC labeling in the samples
with low percentage of stained cells
compared with the strong and diffuse
labeling of most samples and with
progressive fading of the staining be-
tween stained and unstained areas
without clear-cut close positive and
negative cells. Nevertheless, a case
of clear-cut NRASQ61R IHC heteroge-
neity is illustrated by Massi et al. (2014)
with no mention of obvious technical
artifact.www.jidonline.org 337
Figure 1. Example of anti-NRASQ61R immunohistochemistry (clone SP174) in an NRASQ61R mutated
melanoma. Different intensities of staining are seen at (a) low (scale bar ¼ 5 mm) and high magnification
with progression of the signal from (b) weak (scale bar ¼ 0.1 mm), (c) moderate (scale bar ¼ 0.1 mm) to
(d) strong (scale bar ¼ 0.1 mm) staining of tumor cells, supporting technical issues more than true
biological heterogeneity.
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338To conclude, in the absence of a his-
tory of a second primary melanoma, we
believe that first-appearing discordance
between different BRAF and NRAS
mutational status should be first consid-
ered as the failure of the molecular
method to detect the mutation in chal-
lenging samples. Confrontation of the
molecular, IHC, and histologic data
seems to be crucial to avoid false nega-
tivity in challenging samples. We also
propose analyzing many tumor samples
per patient to overcome the drawbacks
of each technique and to detect the
mutations, allowing a targeted therapy
in patients with metastatic melanoma.
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